Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Eliot N. Mostow MD, MPH Associate Editor

Sarah L. Chamlin MD Advisory Board

See All Experts

story of the week

Published in Dermatology

Journal Scan / Research · May 25, 2015

Risk for Serious Infection With Biologic and Systemic Treatment of Psoriasis

JAMA Dermatology

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Steven Feldman MD, PhD

JAMA Dermatology

Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

JAMA Dermatol 2015 May 13;[EPub Ahead of Print], RE Kalb, DF Fiorentino, MG Lebwohl, J Toole, Y Poulin, AD Cohen, K Goyal, S Fakharzadeh, S Calabro, M Chevrier, W Langholff, Y You, CL Leonardi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Risk for Serious Infection With Biologic and Systemic Treatment of Psoriasis

Additional Info

Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

Further Reading

Suicidal and Self-Injurious Behaviors Among Patients With Psoriasis or Psoriatic Arthritis Treated With Biologics

Efficacy and Safety of Combined Topical 17α-Ethinyl Estradiol With Minoxidil vs Topical Minoxidil Alone in Patients With Female Pattern Hair Loss

Efficacy of Treatment With Secukinumab in Patients With Hidradenitis Suppurativa

Clinical Features and Treatment Outcomes Among Patients With Primary Cutaneous B-Cell Lymphomas

Clinical Characteristics and Outcomes of DPP-4 Inhibitor–Associated Bullous Pemphigoid

Efficacy and Safety of Tofacitinib vs Azathioprine in Patients With Alopecia Areata and Its Variants

Outcomes of Down-Titration in Patients With Severe Scalp Alopecia Areata Initially Treated With Baricitinib 4 mg

Association Between 5α-Reductase Inhibitor Use for Dermatologic Conditions and the Risk of Breast or Gynecologic Cancers

Safety and Effectiveness of a Targeted Alkali Thermolysis Patch for the Treatment of Patients With Primary Axillary Hyperhidrosis or Excessive Axillary Sweating

Outcomes of Continued Ritlecitinib Treatment Through Week 48 in Patients With Alopecia Areata With or Without Early Target Responses

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis

Recently Updated